Skip to main content
SpringerLink
Log in

Overview of misoprostol clinical experience

  • Prostaglandins in Peptic Ulcer Disease
  • Clinical Efficacy of Misoprostol
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Misoprostol is an E1 prostaglandin analog. Most of the other synthetic prostaglandins that are being studied in advanced clinical trials for gastrointestinal diseases are E2 derivatives. Misoprostol has shown a dose-related antisecretory effect that lasted 3–5.5 hr. In addition, animal studies have shown cytoprotective properties that are being confirmed in clinical studies. ulcer-healing trials using four times daily dosing appear to parallel the antisecretory dose-response curve up to a dose of 200 μg qid. Evidence presented in this supplement suggests a further increase in healing-rate response at 300 μg misoprostol qid. The misoprostol healing rates obtained in duodenal ulcer and gastric ulcer therapy at 200 μg qid are not significantly different from those seen in the same studies with cimetidine at a dose of 300 mg qid. No significant rebound in recurrence has been observed during follow-up for 12 months after short-term 100- and 200-μg qid misoprostol treatment. The most frequent adverse effects are dose-related diarrhea and abdominal cramping, which are transient in most patients and have not caused a significant problem in clinical use. There is also a tropic effect on the pregnant uterus, which was observed in a special pharmacologic clinical study. No significant abnormalities have been detected in clinical laboratory tests or gastric biopsies. There have also been no adverse effects noted on blood pressure, pulse, platelets, the immune system, pulmonary function, gastrointestinal hormones, or the endocrine system. These previously discussed characteristics of misoprostol, and current data, suggest that this prostaglandin E1 derivative may be an important addition to the treatment of peptic ulcer disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fordtran JS: Dose-response, meal-stimulated gastric antisecretory study of SC-29333 in healthy volunteers. G.D. Searle & Co. Protocol No. MED-80-02-081; Report No. MED-81-06-090, August 1982. Report addendum on serum gastrin determinations, July 1983

  2. Davis GR, Walsh JH, Santa Ana CA, Morawski SG, Fordtran JS: Effect of cimetidine and enprostil on gastric acidity and serum gastrin concentration in normal subjects. Gastroenterology 86(5) pt 2:1058, 1984 (abstract)

    Google Scholar 

  3. Akdamar K, Agrawal N, Ertan A: Inhibition of nocturnal gastric secretion in normal human volunteers by misoprostol: A synthetic prostaglandin E1 methyl ester analog. Am J Gastroenterol 77:902–904, 1982

    Google Scholar 

  4. Single-dose antisecretory effects of SC-29333 against histamine-stimulated gastric secretion. G.D. Searle & Co. Unpublished report No. MED-80-06-053, June 23, 1980

  5. Ene MD, Daneshmend TK, Roberts CJC: The effect of chronic dosing with cimetidine, carbenoxolone, and SC-29333 on gastric acid output in man. Br J Clin Pharmacol 15:611–612, 1983

    Google Scholar 

  6. Comparison of the effects of a single oral dose of misoprostol, cimetidine and placebo on coffee-stimulated gastric secretion in human volunteers. G.D. Searle & Co. Unpublished report No. E29-84-06-018, July 6, 1984

  7. Wilson DE, Quadros E, Rajapaksa T, Adams A, Noar M: Effects of misoprostol on gastric acid and mucus secretion in man. Dig Dis Sci 31(Suppl):126S-129S, 1986

    Google Scholar 

  8. Dajani EZ, Nissen CH: Gastrointestinal cytoprotective effects of misoprostol: Clinical efficacy overview. Dig Dis Sci 30(Suppl):194S-200S, 1985

    Google Scholar 

  9. Hunt JN, Smith JL, Jiang CL, Kessler L: Effect of synthetic prostaglandin E1 analog on aspirin-induced gastric bleeding and secretion. Dig Dis Sci 28(10):897–902, 1983

    Google Scholar 

  10. Cohen MM, Clark L, Armstrong L, D'Souza J: Reduced aspirin-induced fecal blood loss with simultaneous administration of misoprostol (PGE1 methyl analog). Gastroenterology 84:1126, 1983 (abstract)

    Google Scholar 

  11. McGuigan JE, Chang Y, Dajani EZ: Effect of misoprostol, an antiulcer prostaglandin, on serum gastrin in patients with duodenal ulcer. Dig Dis Sci 31(Suppl):120S-125S, 1986

    Google Scholar 

  12. Isenberg JI, Hogan DL, Selling JA, Koss MA: Duodenal bicarbonate secretion in humans: Role of prostaglandins (abstract). Dig Dis Sci 31(Suppl):130S, 1986

    Google Scholar 

  13. Lanza FL: A double-blind study of prophylactic effect of misoprostol on lesions of gastric and duodenal mucosa induced by oral administration of tolmetin in healthy subjects. Dig Dis Sci 31(Suppl):131S-136S, 1986

    Google Scholar 

  14. Silverstein FE, Kimmey MB, Saunders DR, Levine DS: Gastric protection by misoprostol against 1300 mg of aspirin: An endoscopic study. Dig Dis Sci 31(Suppl):137S-141S, 1986

    Google Scholar 

  15. Agrawal NM, Godiwala T, Arimura A, Dajani EZ: Comparative cytoprotective effects against alcohol insult: Misoprostol versus cimetidine. Dig Dis Sci 31(Suppl):142S, 1986

    Google Scholar 

  16. Brand DL, Roufail WM, Thomson ABR, Tapper EJ: Misoprostol, a synthetic PGE1 analog in the treatment of duodenal ulcers: A multicenter double-blind study. Dig Dis Sci 30(Suppl):147S-158S, 1985

    Google Scholar 

  17. Sontag SJ, Mazure PA, Pontes JF, Beker SG, Dajani EZ: Misoprostol in the treatment of duodenal ulcer: A multicenter double-blind placebo-controlled study. Dig Dis Sci 30(Suppl):159S-163S, 1985

    Google Scholar 

  18. Agrawal NM, Saffouri B, Kruss DM, Callison DA, Dajani EZ: Healing of benign gastric ulcer: A placebo-controlled comparison of two dosage regimens of misoprostol, a synthetic analog of prostaglandin E1. Dig Dis Sci 30(Suppl): 164S-170S, 1985

    Google Scholar 

  19. A multicenter international double-blind parallel group comparison of two dosage regimens of misoprostol and cimetidine in the treatment of duodenal ulcer in outpatients. G.D. Searle & Co., Ltd. Unpublished report No. E20-84-06-012, July 20, 1984

  20. Arvanitakis C, Theoharidis A, Giannoulis E, Nikopoulos A, Nakos V, Tourkantonis A: A comparative clinical trial of cimetidine and misoprostol (methyl PGE1) in the treatment of duodenal ulcer. Gastroenterology 86(5) pt 2:1017, 1984 (abstract)

    Google Scholar 

  21. Simon B, Rohner HG, Maier K, Muller P, Dammann HG: Misoprostol and cimetidine in the short-term treatment of duodenal ulcer—a double-blind randomized multicenter study in Germany. Gastroenterology 86(5) pt 2:1253, 1984 (abstract)

    Google Scholar 

  22. A multicenter international double-blind parallel group comparison of two dosage regimens of misoprostol and cimetidine in the treatment of benign gastric ulcer in outpatients. G.D. Searle & Co., Ltd. Unpublished report No. E14-84-06-013, July 6, 1984

  23. A multicenter double-blind trial of misoprostol and placebo in the treatment of duodenal ulcer in outpatients. G.D. Searle & Co. Unpublished report No. N18-84-06-182, November 27, 1984

  24. Ulcer recurrence in posttreatment observation period: Misoprostol with antacid in DU. G.D. Searle & Co. Unpublished report No. N19-84-06-148, November 28, 1984

  25. Multiclinic double-blind controlled comparison of misoprostol and placebo in the treatment of benign gastric ulcer in outpatients. G.D. Searle & Co. Unpublished report No. N13-84-06-096, July 11, 1984

  26. Herting RL, Clay GA: Overview of clinical safety with misoprostol. Dig Dis Sci 30(Suppl):185S-193S, 1985

    Google Scholar 

  27. A study of the effect of misoprostol (SC-29333) on platelet aggregation, respiratory and endocrine function in volunteer subjects. G.D. Searle & Co., Ltd. Unpublished report No. E35-83-06-069, August 24, 1983

  28. Neil GA, Jeejeebhoy KN: Successful treatment of hemorrhagic gastritis with misoprostol (SC-29333). Gastroenterology 86(2):1194, 1984 (abstract)

    Google Scholar 

  29. Placebo-controlled double-blind evaluation of the effect of misoprostol on immunologic competence in normal volunteers. G.D. Searle & Co. Unpublished report No. N36-84-06-062, June 28, 1984

  30. Eliasson R, Posse N: The effect of prostaglandin on the non-pregnant human uterusin vivo. Acta Obstet Gynecol Scand 39:112–126, 1960

    Google Scholar 

  31. Wiquist N: Unpublished observations

  32. Rabe T: Unpublished observations

Download references

Author information

Authors and Affiliations

  1. G.D. Searle & Company, North American Clinical Research and Medical Affairs, Box 5110, 60680, Chicago, Illinois

    R. L. Herting MD, PhD & C. H. Nissen BA

Authors
  1. R. L. Herting MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. H. Nissen BA
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Herting, R.L., Nissen, C.H. Overview of misoprostol clinical experience. Digest Dis Sci 31 (Suppl 2), 47S–54S (1986). https://doi.org/10.1007/BF01309323

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01309323

Keywords

Search

Navigation